Skip to main content

Fiscal Wizard · Single-issue tearsheet

HRMY / Jun 22, 2026 Run #7574

HRMY

Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Composite verdict

A 90.6 / 100
Bullish setup · Trend Following 15 drivers · 2 gates blocking
  • Connors RSI(2)
  • Double 7s
  • Chaikin Money Flow
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 6th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 18 signals0% Bear
Momentum Bullish 89Mean-reversion Neutral 59

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -30%
Asset value $15.03Earnings power value $39.69Price $33.28

The discount is mostly unpriced earnings power: price ($33.28) sits between asset value ($15.03) and no-growth earnings power value ($39.69).

Fundamentals Strong

81.2 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Inventory Turnover 100
OCF to Net Income 0
Asset Turnover 100
Cash Conversion 0
Free Cash Flow Yield 100
Margin of Safety 14

Technicals Bullish

100.0 / 100

Bullish setup leads (Connors RSI(2), Double 7s, Chaikin Money Flow); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Connors RSI(2) 88
Double 7s 84
Vortex Signal 83

Risk Gates

2 blocking 9 caution

2 guards active, 21 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for HRMY.